Company Encyclopedia
View More
name
Femasys
FEMY.US
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women’s healthcare provider organizations.
1.407 T
FEMY.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking129/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-376.23%E
    • Profit Margin-960.53%E
    • Gross Margin59.71%A
  • Growth ScoreB
    • Revenue YoY63.53%A
    • Net Profit YoY-9.38%C
    • Total Assets YoY4.52%C
    • Net Assets YoY-23.68%E
  • Cash ScoreB
    • Cash Flow Margin-10.41%D
    • OCF YoY63.53%A
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreD
    • Gearing Ratio72.03%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    PharmaCyte Biotech stock surges following profitable exit from Femasys investment

    PharmaCyte Biotech Inc. (NASDAQ:PMCB) shares surged 67.8% after successfully monetizing its stake in Femasys Inc. (NASDAQ:FEMY), boosting liquidity. The sale increased PharmaCyte's cash and marketable securities to approximately $20 million, up from $13.3 million.

    MSN·
    US
    PMCB
    +54.22%
    US
    FEMY
    +1.28%
    MSN·
    US
    PMCB
    +54.22%
    US
    FEMY
    +1.28%

    PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment | FEMY Stock News

    PharmaCyte Biotech successfully monetized its stake in Femasys Inc., boosting its cash and marketable securities to $20 million. This move underscores PharmaCyte's strategic capital deployment and commitment to enhancing shareholder value. Despite a strengthened financial position, PharmaCyte's stock trades at $0.65 per share. The company plans to continue pursuing value-accretive investments and disciplined management to further enhance returns.

    StockTitan·
    US
    FEMY
    +1.28%
    US
    PMCB
    +54.22%
    StockTitan·
    US
    FEMY
    +1.28%
    US
    PMCB
    +54.22%

    Femasys shares are trading higher after Laidlaw initiated coverage on the stock with a Buy rating and announced a $6.50 price target.

    benzinga_article·
    US
    FEMY
    +1.28%
    benzinga_article·
    US
    FEMY
    +1.28%

    Femasys: Strategic Advancements and Financial Health Justify Buy Rating

    Jason McCarthy from Maxim Group maintains a Buy rating on Femasys with a $3.00 price target, citing strategic advancements and financial health. Femasys reported increased revenue from FemBloc sales, secured UK regulatory approvals, and partnered with Kebomed for European expansion. Their fertility treatment, FemaSeed, gained FDA clearance. Recent financing activities have strengthened their financial position, supporting growth and market share capture, justifying the Buy rating.

    Tip Ranks·
    US
    FEMY
    +1.28%
    Tip Ranks·
    US
    FEMY
    +1.28%

    Femasys | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 729.39 K

    LB filings·
    US
    FEMY
    +1.28%
    LB filings·
    US
    FEMY
    +1.28%
    © 2025 Longbridge｜Disclaimer